Celera Corporation (CRA)

[surf1944]

7:01AM Celera Genomics publishes data extending the association between the KIF6 gene variant and differential reduction of coronary events from statin therapy to the elderly with prior vascular disease (CRA) 6.98 : Co announces the publication of data reporting that elderly carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy. The effect of pravastatin versus placebo on coronary events according to KIF6 carrier status was investigated among 5,752 patients of the PROspective Study of Pravastatin in the Elderly at Risk study.